HUMALOG (insulin lispro) by Eli Lilly and Company. Approved for insulin analog [epc]. First approved in 1996.
Drug data last refreshed 9m ago · AI intelligence enriched 1w ago
HUMALOG (insulin lispro) is a rapid-acting insulin analog approved in 1996 for diabetes management. It works by mimicking the body's natural insulin response to lower blood glucose levels. HUMALOG is administered via subcutaneous injection and is designed for flexible dosing around meals.
Declining revenue trajectory with moderate competitive pressure (30/100) signals organizational focus shift toward next-generation products and defensive strategies.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog®
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Worked on HUMALOG at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$458M Medicare spend — this is a commercially significant brand
Working on HUMALOG offers stable but declining career trajectory within a mature, commoditizing franchise. Professionals should expect defensive positioning, cost optimization focus, and potential transition opportunities to next-generation insulin analogs or combination therapies within Eli Lilly.